Does Rallies show 13F holders for OVID?

Yes. Rallies tracks hedge fund and 13F ownership data for OVID, including fund names, share counts, latest tracked quarter, and position changes when available.

Is OVID research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.

OVID (Ovid Therapeutics Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Ovid Therapeutics Inc. Common Stock (OVID) is a publicly traded Healthcare sector company. As of May 21, 2026, OVID trades at $2.36 with a market cap of $449.80M and a P/E ratio of 0.00. OVID moved -0.42% today. Year to date, OVID is +43.98%; over the trailing twelve months it is +724.71%. Its 52-week range spans $0.24 to $3.11. Analyst consensus is strong buy with an average price target of $5.33. Rallies surfaces OVID's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns OVID stock?

Hedge funds tracked by Rallies that own OVID include Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ovid Therapeutics Inc. Common Stock.

OVID Key Metrics

Key financial metrics for OVID
Metric	Value
Price	$2.36
Market Cap	$449.80M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.11
52-Week Low	$0.24
Volume	10
Avg Volume	0
Revenue (TTM)	$7.12M
Net Income	$-24.17M
Gross Margin	0.00%

Top Hedge Funds Holding OVID

Mangrove Partners holds 27.29K shares of OVID, changed +0.00% as of Mar 31, 2026.

Latest OVID News

Ovid Therapeutics Doses KCC2 Activator, Raises $60M PIPE, $53.9M Warrants, Ends Q1 with $165.6M — May 12, 2026
Ovid Therapeutics Tops Q4 Estimates with $0.06 EPS, Secures $81M Funding — Mar 18, 2026
Ovid Secures $60M Financing, Shows 7mg OV329 Safety and Clears OV4071 — Mar 18, 2026
Ovid Therapeutics Raises $60M Via Private Placement to Fund OV329 Expansion — Mar 18, 2026
Ovid Therapeutics to Present at Feb. 25, Mar. 4 and Mar. 11 Investor Conferences — Feb 25, 2026

Recent OVID Insider Trades

ALEXANDER MARGARET A. sold 11.66K (~$16.90K) on Feb 23, 2026.
Rona Jeffrey A sold 8.54K (~$12.38K) on Feb 23, 2026.
ALEXANDER MARGARET A. sold 5.28K (~$2.96K) on Feb 26, 2025.

OVID Analyst Consensus

8 analysts cover OVID: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.33.

Common questions about OVID

Who owns OVID stock?: Hedge funds tracked by Rallies that own OVID include Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ovid Therapeutics Inc. Common Stock.
Does Rallies show 13F holders for OVID?: Yes. Rallies tracks hedge fund and 13F ownership data for OVID, including fund names, share counts, latest tracked quarter, and position changes when available.
Is OVID research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.